After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

After winning a breakthrough therapy designation for its Hunter syndrome enzyme replacement therapy, Denali Therapeutics is ...

Relying on a single strand of hair, LinusBio is launching its diagnostic aid for autism spectrum disorder—with a test ...

In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...

Kura and Kyowa used the announcement to confirm that they are on track to file a new drug approval application with the FDA ...

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs ...

X4 Pharmaceuticals is laying off 30% of its staff and halting preclinical R&D as the immune system specialist channels its resources into recently approved rare disease drug mavorixafor.

AstraZeneca has ended development of its oral factor D inhibitor vemircopan, triggering a $753 million impairment charge as ...

Cancer biotech Viracta Therapeutics has closed its doors, laying off all employees and winding down operations.

Glucotrack has cleared the first human clinical study of its long-term continuous glucose monitoring implant, designed to ...

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the ...

Precision medicines biotech Frontier Medicines is leaving behind an unknown number of staffers as it refocuses resources to ...